Drug Trial Radar · NCT01523171
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
Last checked: Nov 21, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
97
Actual
Start
Apr 30, 2012
Primary completion
Apr 30, 2014
Study completion Apr 30, 2014
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Feb 1, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To evaluate the efficacy of once daily dose of SAR302503 in subjects previously treated with ruxolitinib and with a current diagnosis of intermediate-1 with symptoms, Intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), or post-essential thrombocythemia myelofibrosis (Post-ET MF) based on the reduction of spleen volume at the end of 6 treatment cycles; Secondary Objectives: * To evaluate the effect of SAR302503 on Myelofibrosis (MF) associated symptoms as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary * To evaluate the durability of splenic response * To evaluate the splenic response to SAR302503 by palpation at the end of Cycle 6 * To evaluate the splenic response to SAR302503 at the end of Cycle 3 * To evaluate the effect of SAR302503 on the Janus kinase 2 (JAK2) V617F allele burden * To evaluate the safety and tolerability of SAR302503 in this population * To evaluate plasma concentrations of SAR302503 for population PK analysis, if warranted
Conditions
- Hematopoietic Neoplasm
Interventions
SAR302503Drug
Pharmaceutical form:capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response Rate: Percentage of Participants With >=35% Reduction From Baseline in Spleen Volume at End of Cycle 6Time frame: Baseline, End of Cycle 6
Locations
42 sites in 10 countries. Site status is shown where the registry gives one.
Investigational Site Number 840007
Phoenix, Arizona
Investigational Site Number 840003
San Francisco, California
Investigational Site Number 840004
San Francisco, California
Investigational Site Number 840005
Atlanta, Georgia
Investigational Site Number 840014
Chicago, Illinois
Investigational Site Number 840001
Kansas City, Kansas
Investigational Site Number 840017
Baltimore, Maryland
Investigational Site Number 840013
Baltimore, Maryland
Investigational Site Number 840010
Ann Arbor, Michigan
Investigational Site Number 840009
New York, New York
Investigational Site Number 840018
New York, New York
Investigational Site Number 840022
Cleveland, Ohio
Investigational Site Number 840019
Middletown, Ohio
Investigational Site Number 840024
Charleston, South Carolina
Investigational Site Number 840002
Houston, Texas
Investigational Site Number 840015
Salt Lake City, Utah
Investigational Site Number 040002
Salzburg, Austria
Investigational Site Number 040001
Vienna, Austria
Investigational Site Number 056002
Antwerp, Belgium
Investigational Site Number 056003
Leuven, Belgium
Investigational Site Number 124001
Toronto, Canada
Investigational Site Number 250001
Marseille, France
Investigational Site Number 250003
Nîmes, France
Investigational Site Number 250002
Paris, France
Investigational Site Number 250006
Paris, France
Investigational Site Number 250004
Toulouse, France
Investigational Site Number 276003
Frankfurt am Main, Germany
Investigational Site Number 276007
Leipzig, Germany
Investigational Site Number 276006
Magdeburg, Germany
Investigational Site Number 276001
Mannheim, Germany
Investigational Site Number 276005
Ulm, Germany
Investigational Site Number 380004
Florence, Italy
Investigational Site Number 380001
Milan, Italy
Investigational Site Number 380002
Roma, Italy
Investigational Site Number 380003
Varese, Italy
Investigational Site Number 528002
Amsterdam, Netherlands
Investigational Site Number 528003
Maastricht, Netherlands
Investigational Site Number 528001
Nijmegen, Netherlands
Investigational Site Number 724001
Barcelona, Spain
Investigational Site Number 724003
Majadahonda, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.